Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.

doi:10.1111/adb.12207

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.

Addiction biology - 1 Mar 2016

Kranzler Henry R, Armeli Stephen, Wetherill Reagan, Feinn Richard, Tennen Howard, Gelernter Joel, Covault Jonathan, Pond Timothy

Abstract excerpt

Previous studies indicate that topiramate reduces alcohol use among problem drinkers, with one study showing that the effect was moderated by a polymorphism (rs2832407) in GRIK1, the gene encoding the GluK1 kainate subunit. We examined whether the interactive effect of medication and genotype (1) altered the association between daily self-efficacy and later-day drinking; and (2) had an indirect effect on drinking...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alcohol Drinking

Share to Fructose

Share to Heterozygote

Share to Homozygote

Share to Neuroprotective Agents

Share to Receptors, Kainic Acid

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 25496338
DOI: 10.1111/adb.12207
PMCID: PMC4468044

Genes

GRIK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking.PMID 25496338Read ↗

GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink.Semantic proximity Read ↗

GRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.Semantic proximity Read ↗

An intensive longitudinal examination of topiramate treatment for alcohol use disorder: a secondary analysis of data from a randomized controlled trial.Semantic proximity Read ↗

Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

Posttreatment effects of topiramate treatment for heavy drinking.Semantic proximity Read ↗

Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder.Semantic proximity Read ↗

Topiramate's reduction of body mass index in heavy drinkers: lack of moderation by a GRIK1 polymorphism.Semantic proximity Read ↗

Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.Semantic proximity Read ↗

Balancing risk and benefit in heavy drinkers treated with topiramate: implications for personalized care.Semantic proximity Read ↗

A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.Semantic proximity Read ↗

Molecular correlates of topiramate and <i>GRIK1</i> rs2832407 genotype in pluripotent stem cell-derived neural culturesSemantic proximity Read ↗

Molecular Correlates of Topiramate and GRIK1 rs2832407 Genotype in Pluripotent Stem Cell-Derived Neural Cultures.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.